Xianbao He1, Jared J Eddy1, Karen R Jacobson1, Andrew J Henderson1,2, Luis M Agosto1. 1. Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA. 2. Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Mycobacterium tuberculosis (Mtb) and human immunodeficiency virus (HIV) coinfection increases mortality, accelerates progression to acquired immune deficiency syndrome, and exacerbates tuberculosis disease. However, the impact of pre-existing Mtb infection on subsequent HIV infection has not been fully explored. We hypothesized that Mtb infection creates an immunological environment that influences the course of HIV infection, and we investigated whether pre-existing Mtb infection impacts the susceptibility of CD4+ T cells to HIV-1 infection. METHODS: Plasma and blood CD4+ T cells isolated from HIV-negative individuals across the Mtb infection spectrum and non-Mtb-infected control individuals were analyzed for inflammation markers and T-cell phenotypes. CD4+ T cells were infected with HIV-1 in vitro and were monitored for viral replication. RESULTS: We observed differences in proinflammatory cytokines and the relative proportion of memory T-cell subsets depending on Mtb infection status. CD4+ T cells derived from individuals with latent Mtb infection supported more efficient HIV-1 transcription, release, and replication. Enhanced HIV-1 replication correlated with higher percentages of CD4+ TEM and TTD cells. CONCLUSIONS: Pre-existing Mtb infection creates an immunological environment that reflects Mtb infection status and influences the susceptibility of CD4+ T cells to HIV-1 replication. These findings provide cellular and molecular insights into how pre-existing Mtb infection influences HIV-1 pathogenesis.
BACKGROUND: Mycobacterium tuberculosis (Mtb) and human immunodeficiency virus (HIV) coinfection increases mortality, accelerates progression to acquired immune deficiency syndrome, and exacerbates tuberculosis disease. However, the impact of pre-existing Mtb infection on subsequent HIV infection has not been fully explored. We hypothesized that Mtb infection creates an immunological environment that influences the course of HIV infection, and we investigated whether pre-existing Mtb infection impacts the susceptibility of CD4+ T cells to HIV-1 infection. METHODS: Plasma and blood CD4+ T cells isolated from HIV-negative individuals across the Mtb infection spectrum and non-Mtb-infected control individuals were analyzed for inflammation markers and T-cell phenotypes. CD4+ T cells were infected with HIV-1 in vitro and were monitored for viral replication. RESULTS: We observed differences in proinflammatory cytokines and the relative proportion of memory T-cell subsets depending on Mtb infection status. CD4+ T cells derived from individuals with latent Mtb infection supported more efficient HIV-1 transcription, release, and replication. Enhanced HIV-1 replication correlated with higher percentages of CD4+ TEM and TTD cells. CONCLUSIONS: Pre-existing Mtb infection creates an immunological environment that reflects Mtb infection status and influences the susceptibility of CD4+ T cells to HIV-1 replication. These findings provide cellular and molecular insights into how pre-existing Mtb infection influences HIV-1 pathogenesis.
Authors: I M Orme; E S Miller; A D Roberts; S K Furney; J P Griffin; K M Dobos; D Chi; B Rivoire; P J Brennan Journal: J Immunol Date: 1992-01-01 Impact factor: 5.422
Authors: E W Bunyasi; H Geldenhuys; H Mulenga; J Shenje; A K K Luabeya; M Tameris; E Nemes; H Mahomed; V Rozot; R Wood; T Scriba; J R Andrews; M Hatherill Journal: Int J Tuberc Lung Dis Date: 2019-05-01 Impact factor: 2.373
Authors: Fabiana A Zambuzi; Priscilla M Cardoso-Silva; Milena S Espindola; Luana S Soares; Leonardo J Galvão-Lima; Verônica S Brauer; Matheus S Gomes; Laurence R Amaral; Matthew Schaller; Valdes R Bollela; Fabiani G Frantz Journal: Cytokine Date: 2016-08-31 Impact factor: 3.861
Authors: Z Toossi; J L Johnson; R A Kanost; M Wu; H Luzze; P Peters; A Okwera; M Joloba; P Mugyenyi; R D Mugerwa; H Aung; J J Ellner; C S Hirsch Journal: J Acquir Immune Defic Syndr Date: 2001-09-01 Impact factor: 3.731
Authors: Cheleka A M Mpande; One B Dintwe; Munyaradzi Musvosvi; Simbarashe Mabwe; Nicole Bilek; Mark Hatherill; Elisa Nemes; Thomas J Scriba Journal: Front Immunol Date: 2018-03-01 Impact factor: 7.561
Authors: María B Arriaga; Mariana Araújo-Pereira; Beatriz Barreto-Duarte; Caio Sales; João Pedro Miguez-Pinto; Evelyn B Nogueira; Betânia M F Nogueira; Michael S Rocha; Alexandra B Souza; Aline Benjamin; Jamile G de Oliveira; Adriana S R Moreira; Artur T L Queiroz; Moreno M S Rodrigues; Renata Spener-Gomes; Marina C Figueiredo; Betina Durovni; Solange Cavalcante; José R Lapa-E-Silva; Afrânio L Kristki; Marcelo Cordeiro-Santos; Timothy R Sterling; Valeria C Rolla; Bruno B Andrade Journal: Front Med (Lausanne) Date: 2022-01-21
Authors: Rachel A Bender Ignacio; Jessica Long; Aparajita Saha; Felicia K Nguyen; Lara Joudeh; Ethan Valinetz; Simon C Mendelsohn; Thomas J Scriba; Mark Hatherill; Holly Janes; Gavin Churchyard; Susan Buchbinder; Ann Duerr; Javeed A Shah; Thomas R Hawn Journal: PLoS One Date: 2022-05-03 Impact factor: 3.752
Authors: Kevin Wong; James Nguyen; Lillie Blair; Marina Banjanin; Bunraj Grewal; Shane Bowman; Hailey Boyd; Grant Gerstner; Hyun Jun Cho; David Panfilov; Cho Ki Tam; Delaney Aguilar; Vishwanath Venketaraman Journal: J Clin Med Date: 2020-11-06 Impact factor: 4.241